Patient group
Erwachsene mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD), die Anti-Aquaporin- 4-Immunglobulin-G(AQP4-IgG)-seropositiv sind
completed2022-08-01D series
Inebilizumab
Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv
Open official case page ↗
- Brand
- Uplizna
- Manufacturer
- Horizon Therapeutics GmbH
G-BA action
final resolution
2023-01-19
Arzneimittel-Richtlinie/Anlage XII: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)
Evidence-checked summary
The G-BA found no proven added benefit for Erwachsene mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD), die Anti-Aquaporin- 4-Immunglobulin-G(AQP4-IgG)-seropositiv sind. The appropriate comparator was Therapie nach ärztlicher Maßgabe. The G-BA issued a final resolution on 2023-01-19. The official page states that it took effect as follows: 19.01.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2022-12-05
84 parsed turns
Oral hearing: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)
Official Wortprotokoll · 14 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A22-74
matched
Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
Official assessment PDF · 48 pages
G-BA decisions
Distinct actions and documents
2023-01-19
final resolution
Arzneimittel-Richtlinie/Anlage XII: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)
The G-BA found no proven added benefit for Erwachsene mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD), die Anti-Aquaporin- 4-Immunglobulin-G(AQP4-IgG)-seropositiv sind. The appropriate comparator was Therapie nach ärztlicher Maßgabe. The G-BA issued a final resolution on 2023-01-19. The official page states that it took effect as follows: 19.01.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗annex xii current versionInebilizumabOpen ↗comparator informationInformationen zur zweckmäßigen VergleichstherapieOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiGOpen ↗
Generic graph relations · 5
HAS ASSESSMENTInebilizumabHAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)HAS HEARINGOral hearing: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)OWNS DOCUMENTInebilizumabOWNS DOCUMENTInformationen zur zweckmäßigen Vergleichstherapie